About Alzheon, Inc. (adapted from Alzheon, Inc. prospectus):
They are a clinical stage biopharmaceutical company with a Phase 3-ready program in Alzheimers disease and a discovery platform of small molecules for the inhibition of protein misfolding in neurodegenerative disorders.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.